Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Central Pharmaceuticals's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Central Pharmaceuticals was 39.63. The lowest was 4.25. And the median was 5.26.
DHA:CENTRALPHL's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.87 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Central Pharmaceuticals (DHA:CENTRALPHL) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Central Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
11.50
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceuticals Median PS Value Related Terms
Central Pharmaceuticals Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:CENTRALPHL vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceuticals Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Central Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Central Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0.302.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceuticals (DHA:CENTRALPHL) has a Median PS Value of BDT0.00 as of Jul. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Central Pharmaceuticals and its competitors. Over the past decade, Central Pharmaceuticals' Median PS Value has ranged from 4.25 to 39.63. According to the industry distribution chart, Central Pharmaceuticals ranks #999999 out of 545 companies in the Drug Manufacturers industry.
Is Central Pharmaceuticals' Median PS Value too high?
Central Pharmaceuticals' current Median PS Value is BDT0.00. Over the past 10 years, this metric has ranged from a low of 4.25 to a high of 39.63. Based on the distribution chart, Central Pharmaceuticals ranks #999999 out of 545 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Central Pharmaceuticals ranks #999999 out of 545 companies for Median PS Value. This places Central Pharmaceuticals in the lower half of its industry. The industry median Median PS Value is 0.87. Historically, Central Pharmaceuticals' own Median PS Value has ranged from 4.25 to 39.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Central Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceuticals's current Median PS Value is BDT0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.04, compared to a current price of BDT11.50 — trading 4.5% below its estimated fair value. The current Median PS Value is BDT0.00. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current Median PS Value is BDT0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?
Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT11.50 is trading 4.5% below its estimated GF Value™ of BDT12.04.
GuruFocus considers Central Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:CENTRALPHL:
Median PS Value: BDT0.00
GF Value™: BDT12.04 vs. price of BDT11.50 (4.5% below fair value)
No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score
Get the complete analysis for DHA:CENTRALPHL
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:CENTRALPHL has been successfully added to your 
